Table 1.
Comparison of metrics on NASs, generics, and WHO prequalified generics (2019–2020).
| Country | Mozambique | Namibia | South Africa | Tanzania | Zambia | Zimbabwe | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | 2019 | 2020 | 2019 | 2020 | 2019a | 2020b | 2019 | 2020 | 2019 | 2020 | 2019 | 2020 |
| NASs | ||||||||||||
| Received | 0 | 0 | 14 | 0 | 11 | 57 | 1 | 0 | 0 | 0 | 8 | 4 |
| Approved | 0 | 0 | 14 | 0 | 43 | 97 | 1 | 0 | 9 | 1 | 4 | 0 |
| Generics | ||||||||||||
| Received | 198 | 339 | 132 | 227 | 29 | 331 | 858 | 631 | 574 | 206 | 195 | 179 |
| Approved | 291 | 278 | 70 | 46 | 156 | 165 | 591 | 499 | 454 | 217 | 122 | 107 |
| WHO-prequalified generics | ||||||||||||
| Received | 10 | 15 | 8 | 4 | 0 | N/A | 14 | 7 | 11 | 28 | 5 | 9 |
| Approved | 8 | 9 | 8 | 1 | 0 | 0 | 14 | 7 | 11 | 28 | 7 | 7 |
NASs, new active substances; WHO, World Health Organization; N/A, Not available.
a
Data is for August to December due to closure of the agency for part of the year.
b
Data for business as usual only. Excludes backlog.